Press Release                  Theralase Applies to TSX Venture Exchange for Warrant ExtensionToronto, ON – March 28, 2013...
Upcoming SlideShare
Loading in …5
×

Theralase Applies to TSX Venture Exchange for Warrant Extension

225 views

Published on

Theralase Technologies Inc. (TSXV: TLT) (“Theralase”) announced today that it has made application to the TSX Venture Exchange for approval to extend the expiry date of its outstanding common share purchase warrants.

Published in: Investor Relations
  • Be the first to comment

  • Be the first to like this

Theralase Applies to TSX Venture Exchange for Warrant Extension

  1. 1. Press Release Theralase Applies to TSX Venture Exchange for Warrant ExtensionToronto, ON – March 28, 2013 - Theralase Technologies Inc. (TSXV: TLT) (“Theralase”) announced todaythat it has made application to the TSX Venture Exchange for approval to extend the expiry date of itsoutstanding common share purchase warrants.Theralase has applied to have the expiry date of the warrants amended from April 13, 2013 to April 13,2017 for the 1,500,000 total warrants issued on April 13, 2012. The exercise price of the warrantsremains unchanged at $0.38 per warrant, with the exception that the warrants will be cancelled if theyare not exercised within thirty (30) days from written notice that the closing price of Theralase’scommon shares had been $0.75 or greater for 10 consecutive trading days.About Theralase Technologies Inc.:Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralasetechnology is safe and effective in treating pain, inflammation and for tissue regeneration of neuralmuscular skeletal conditions and wound healing. Theralase is currently developing proprietary PhotoDynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses whenlight activated by Theralase’s proprietary and patented laser technology.For further information please visit www.theralase.com , regulatory filings may be viewed by visitingwww.sedar.com.This press release contains forward-looking statements, which reflect the Companys current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation toupdate these forward-looking statements.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) acceptsresponsibility for the adequacy or accuracy of this release.For More Information:Roger Dumoulin-WhitePresident & CEO416-699-5273 ext. 225rwhite@theralase.comKristina HacheyChief Financial Officer416-699-5273 ext. 224khachey@theralase.comGreg BewshDirector of Investor Relations416-699-5273 ext. 258gbewsh@theralase.com

×